Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas Clinical Trial

Official title:

Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02739633
• Other study ID #: Genexol-PM PC
• Status: Recruiting
• Phase: Phase 2
• First received: March 21, 2016
• Last updated: April 16, 2018
• Start date: April 2016
• Est. completion date: December 2019

Study information

• Verified date: April 2018
• Source: Samyang Biopharmaceuticals Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas.

Description:

The aim of the this phase II study is to assess the efficacy and safety of a combination treatment of Genexol®-PM plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 47
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Patient has definitive histologically or cytologically confirmed recurrent and metastatic adenocarcinoma of the pancreas. The definitive diagnosis of recurrent and metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic data. Patients with islet cell neoplasms are excluded.

2. Initial diagnosis of recurrent and metastatic disease must have occurred =6 weeks prior to randomization in the study.

3. Patient has one or more lesions measurable by CT scan or MRI (if patient is allergic to CT contrast media).

4. Male or non-pregnant and non-lactating female, and = 20 years of age.

5. Patient must meet the following blood counts at Baseline (obtained =14 days prior to randomization):

• Absolute neutrophil count (ANC) = 1.5 × 10^9/L

• Platelet count = 100,000/mm3 (100 × 10^9/L)

• Hemoglobin (Hgb) = 9 g/dL.

6. Patient has the following blood chemistry levels at Baseline (obtained =14 days prior to randomization):

• AST (SGOT), ALT (SGPT) = 2.5 × upper limit of normal range (ULN), unless liver metastases are clearly present, then = 5 × ULN is allowed.

• Total bilirubin =ULN

7. Patient has a Karnofsky performance status (KPS) = 70. Two observers will be required to assess KPS. If discrepant, the one with the lowest assessment will be considered true.

8. Patient has voluntarily agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities.

Exclusion Criteria:

1. History of malignancy in the last 5 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.

2. Patients have uncontrolled bacterial, viral, or fungal infections

3. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C.

4. Patients have a history of allergy or hypersensitivity to any of Paclitaxel, Gemcitabine, or Cremophor EL.

5. Patients with high cardiovascular risk, including recent coronary stenting or myocardial infarction in the past 6 months.

6. History of Peripheral Artery Disease (e.g,. claudication, Leo Buerger's disease).

Related Conditions & MeSH terms

• Adenocarcinoma
• Metastatic Adenocarcinoma of the Pancreas
• Recurrent Adenocarcinoma of the Pancreas

Intervention

Drug:
• Genexol-PM
125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
• Gemcitabine
1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.

Locations

Country	Name	City	State
Korea, Republic of	Samyang Biopharmaceuticals	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samyang Biopharmaceuticals Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR) as assessed by RECIST.	ORR will be summarized as the percentage of participants who achieved a confirmed complete (CR) or partial response (PR) using RECIST guidelines.; Response is confirmed at least 4 weeks later.	8 weeks
Secondary	Progression free survival (PFS)	Time from the date of enrollment until the date of objective disease progression or the date of death.; PFS will be summarized using Kaplan-Meier methods.	2 years
Secondary	Overall survival (OS)	OS will be summarized using Kaplan-Meier methods.	2 years
Secondary	Disease control rate (DCR)	DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease	8 weeks
Secondary	Number of participants with adverse events	A adverse event (AE) is as any AE occurring or worsening on or after the first treatment of any study drug, and within 21 days after the last dose of the last study drug.; Severity grades according to NCI CTCAE version 4.0.	Baseline up to Day 21 after the last dose of study treatment